CARA Logo

Cara Therapeutics, Inc. (CARA) 

NASDAQ
Market Cap
$16.73M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
471 of 774
Rank in Industry
249 of 432

Largest Insider Buys in Sector

CARA Stock Price History Chart

CARA Stock Performance

About Cara Therapeutics, Inc.

Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing …

Insider Activity of Cara Therapeutics, Inc.

Over the last 12 months, insiders at Cara Therapeutics, Inc. have bought $0 and sold $42,686 worth of Cara Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Cara Therapeutics, Inc. have bought $0 and sold $1.33M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 1,000,000 shares for transaction amount of $18.19M was made by RHO Ventures VI LP (10 percent owner) on 2017‑03‑31.

List of Insider Buy and Sell Transactions, Cara Therapeutics, Inc.

2024-11-04SalePRESIDENT AND CEO
3,668
0.0066%
$0.29$1,064+13.78%
2024-08-01SalePRESIDENT AND CEO
4,149
0.0075%
$0.35$1,452-12.99%
2024-05-02SalePRESIDENT AND CEO
3,936
0.007%
$0.75$2,952-55.84%
2024-04-05SaleSEC'Y; CHIEF COMPLIANCE & G.C.
2,753
0.0048%
$0.83$2,285-60.19%
2024-04-05SaleCHIEF MEDICAL OFFICER
2,753
0.0048%
$0.83$2,285-60.19%
2024-02-29SalePRESIDENT AND CEO
5,834
0.0115%
$0.89$5,192-56.50%
2024-02-29SaleSEC'Y; CHIEF COMPLIANCE & G.C.
3,293
0.0065%
$0.89$2,931-56.50%
2024-02-29SaleCHIEF MEDICAL OFFICER
3,293
0.0065%
$0.89$2,931-56.50%
2024-02-08SalePRESIDENT AND CEO
35,575
0.0607%
$0.53$18,855+12.12%
2024-02-01SalePRESIDENT AND CEO
4,981
0.0088%
$0.55$2,740+2.58%
2023-11-02SalePresident and CEO
3,796
0.0072%
$1.22$4,631-44.50%
2023-08-03SalePresident and CEO
4,307
0.0077%
$3.07$13,222-72.76%
2023-06-23SaleChief Scientific Off,SVP-R&D
2,993
0.0056%
$3.51$10,505-72.46%
2023-06-23SaleSec'y; Chief Compliance & G.C.
2,483
0.0046%
$3.51$8,715-72.46%
2023-06-23SaleChief Medical Officer
2,723
0.0051%
$3.51$9,558-72.46%
2023-05-05SalePresident and CEO
3,869
0.0072%
$4.40$17,024-71.98%
2023-04-04SaleChief Scientific Off,SVP-R&D
2,733
0.0053%
$4.91$13,419-66.14%
2023-04-04SaleSec'y; Chief Compliance & G.C.
2,481
0.0048%
$4.91$12,182-66.14%
2023-04-04SaleChief Medical Officer
2,481
0.0048%
$4.91$12,182-66.14%
2023-03-03SalePresident and CEO
5,987
0.0105%
$9.71$58,134-76.65%

Insider Historical Profitability

5.24%
RHO Ventures VI LP10 percent owner
3568057
6.5045%
$0.3140+18.29%
ALTA BIOPHARMA PARTNERS III LP10 percent owner
1753447
3.1965%
$0.3110+7.74%
Schoell JosefChief Financial Officer
28000
0.051%
$0.3111<0.0001%
VOGELBAUM MARTINdirector
20160
0.0368%
$0.3132+32.73%
Stauffer Joseph WilliamChief Medical Officer
2000
0.0036%
$0.3111<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
BlackRock$3.11M6.263.42M-3.74%-$120,934.44<0.0001
The Vanguard Group$2.26M4.542.48M-5.69%-$136,326.14<0.0001
Disciplined Growth Investors Inc Mn$1.65M3.321.82M+0.16%+$2,691.780.03
Chescapmanager Llc$1.55M3.111.7M-2.85%-$45,501.820.26
Farallon Capital$1.42M2.851.56M0%+$00.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.